SAB Biotherapeutics, Inc. filed its quarterly report on Form 10-Q for the period ended June 30, 2026, disclosing a net loss of $22.491 million for the second quarter and $41.360 million for the first half of the year, alongside a significant expansion of its balance sheet following a public offering completed in March 2026.
Key Highlights
- Q2 2026 net loss: $22.491 million, compared to $10.114 million in Q2 2025.
- Six-month net loss: $41.360 million for the six months ended June 30, 2026, versus $15.311 million for the same period in 2025.
- Total assets: $238.210 million as of June 30, 2026, up from $172.810 million at December 31, 2025.
- Short-term and long-term investments: $94.365 million and $105.346 million, respectively, as of June 30, 2026.
- March 2026 Public Offering: The company issued common stock and prefunded warrants, raising net proceeds reflected as $79.251 million and an additional $7.238 million from the underwriters' option exercise.
- Common shares outstanding: 90,986,368 as of August 3, 2026, up from 47,609,899 at December 31, 2025.
- Accumulated deficit: $152.255 million at June 30, 2026, compared to $110.895 million at December 31, 2025.
SAB Biotherapeutics Reports Rising R&D Costs and Growing Investment Portfolio in First Half 2026
According to the filing, total operating expenses for the three months ended June 30, 2026 were $23.377 million, more than double the $9.732 million reported in the same quarter of 2025. Research and development expenses accounted for $16.172 million of that total in Q2 2026, compared to $6.997 million in Q2 2025. General and administrative expenses were $7.205 million in Q2 2026, up from $2.735 million a year earlier. For the six-month period, total operating expenses reached $43.375 million versus $20.504 million in the prior-year period, the company disclosed.
The filing reports that other income for the six months ended June 30, 2026 was $2.015 million, driven primarily by interest income of $2.756 million, partially offset by a $1.593 million unfavorable change in the fair value of warrant liabilities. Basic and diluted loss per common share was $(0.28) for Q2 2026 and $(0.62) for the six-month period, based on weighted-average shares outstanding of 79,753,100 and 66,768,309, respectively, according to the filing.
The company's balance sheet grew materially during the period, the filing shows. Total stockholders' equity stood at $214.785 million as of June 30, 2026, compared to $151.495 million at December 31, 2025. Cash and cash equivalents were $8.267 million at June 30, 2026, down from $10.503 million at year-end 2025, while combined short-term and long-term investments totaled $199.711 million. The March 2026 Public Offering and related underwriters' option, together with conversions of Series B Preferred Stock and warrant exercises, contributed to the increase in shares issued and additional paid-in capital during the period, according to the filing. Common stock traded on The Nasdaq Stock Market LLC under the symbol SABS, with warrants trading under SABSW.
What Was Disclosed
SAB Biotherapeutics disclosed its unaudited condensed consolidated financial results for Q2 and the first half of 2026, showing increased operating losses driven by higher research and development and general and administrative expenses, alongside balance sheet growth from its March 2026 public offering.




Please wait processing your request...